Board Member
CytomX Therapeutics, Inc. (CTMX)Equibles does not estimate personal net worth.
Get an email with a short summary when Cardiff Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CRDF alertsMani Mohindru is recorded as CEO at Cardiff Oncology, Inc. (CRDF) and Board Member at CytomX Therapeutics, Inc. (CTMX). The newest filing on record that lists Mani Mohindru as CEO at Cardiff Oncology, Inc. (CRDF) is dated April 23, 2026. The newest filing on record that lists Mani Mohindru as Board Member at CytomX Therapeutics, Inc. (CTMX) is dated April 30, 2026. Cardiff Oncology, Inc. reported in an 8-K filed January 27, 2026 that Mani Mohindru was appointed interim CEO, effective January 27, 2026. Mani Mohindru has spoken on 2 investor events across 1 company, most recently for Cardiff Oncology, Inc. on June 4, 2026. Cardiff Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. CytomX Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cardiff Oncology, Inc. includes Mani Mohindru, Ph.D. (CEO), Mark Erlander (CEO), Mark Erlander, Ph.D. (CEO) and 7 others.
“The Board of Directors of the Company has appointed Dr. Mani Mohindru, a member of the Company's Board of Directors, as interim CEO of the Company.”
“You know, we are focused on a target known as pololikinase 1, PLK1 inhibitor. It is an oral molecule. Interestingly, we are one of the few companies where we are ready to take this molecule into phase 3.”
“Given the technical difficulties, I'm going to take over. Joining the call today with me from the oncology team will be me, myself, the entrant CEO.”
Start not stated–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CEO
